TABLE 3

Examples (nonexhaustive) of xenobiotic compounds from the University of Washington Drug Interaction Database whose pharmacokinetics or pharmacodynamics have been reported to be affected by non-P450 oxidative enzymes since 2010

EnzymeAffected DrugAffected PropertyOverall Effect
ALDHAcetaldehydePK↑ AUC, Cmax
EthanolPD↑ Facial skin blood flow, heart rate
AOXK-469PK↓ Clearance
CES (CES1 or CES2)ClopidogrelPK↑ AUC, Cmax; ↓ metabolite/parent
EnalaprilatPD↓ Maximum platelet aggregation
OseltamivirPK↓ AUC
PK↑ AUC, Cmax; ↓ metabolite/parent
Carbonyl reductaseDaunorubicinPK↑ AUC; ↓ clearance
Catechol-O-methyltransferaseMDMAPD↓ Blood pressure
PaliperidonePK↓ AUC
Epoxide hydrolaseCarbamazepinePK↑ Dose
WarfarinPK↓ Dose
FMODanusertibPK↑ Clearance
ItopridePK↑ AUC, Cmax; ↓ clearance
Sulindac sulfidePK↑ AUC
N-AcetyltransferaseN-AcetylretigabinePK↓ AUC
SulfapyridinePK↑ AUC
SulfamethoxazolePK↑ AUC
IsoniazidPK↑ AUC
PhenytoinPK↑ AUC, Cmax; ↓ clearance
  • The University of Washington Drug Interaction Database is available at https://didb.druginteractioninfo.org (accessed May 10, 2016). AUC, area under the curve; MDMA, 3,4-methylenedioxymethamphetamine; PD, pharmacodynamics; PK, pharmacokinetics; UDPGA, UDP glucuronic acid; XK-469, 2-(4-((7-chloro-2-quinoxalinyl)oxy)­phenoxy)­propionic acid. Increases and decreases in overall effect parameters are indicated by up and down arrows, respectively.